Cybin

Psilocybin
#Cybin #Depression #Major depressive disorder #Phase II trial #Psilocybin

Psychedelic antidepressant trial shows rapid and robust response

Phase II interim data for psilocybin analog CYB003 in major depressive disorder (MDD) showed rapid, robust, and clinically significant reduction of depression symptoms. Of the trial participants, 53.3% responded and 20% are in remission (i.e. no longer meeting the clinical definition of depression) after a single… Read More

#News

#Clinical trial #Cybin #Major depressive disorder #Psychedelics

Another milestone achieved in major depressive disorder trial 

Cybin, a clinical-stage biopharmaceutical company developing psychedelic-based treatment options for mental health, has completed dosing in Cohort 5 of a Phase II trial evaluating CYB003, an investigational proprietary deuterated analog of psilocybin for the potential treatment of major depressive disorder (MDD).   The dosing was completed with no… Read More

#News